HLN NYSE
Credit Risk of going bust: lower than 82% of companies Debt: 19.6% of company value Bonds: none of note held by US funds details ▾
Total debt $10.95B against a stock market value of $44.86B.
Distance to default 10.07 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $6.70B (short-term plus half of long-term), stock volatility 23.4%; Altman Z'' 3.98. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Weybridge, SU KT13 0NY
GB
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.